within Pharmacolibrary.Drugs.ATC.A;

model A07AA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07AA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Paromomycin is an aminoglycoside antibiotic primarily used orally for the treatment of intestinal protozoal infections such as amoebiasis, giardiasis, and as a second-line agent for certain cases of leishmaniasis. It is approved and still used for such indications, notably as an antiparasitic and to treat some cases of hepatic encephalopathy due to bacterial overgrowth.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data are sparse for paromomycin, as it is poorly absorbed (<1%) from the gastrointestinal tract in healthy adults. Some older studies in healthy volunteers report limited to no systemic absorption following oral administration.</p><h4>References</h4><ol><li><p>K Pinjari, MJS, et al., &amp; Gilhotra, RM (2017). Investigation of . <i>Indian journal of pharmacology</i> 49(4) 297–303. DOI:<a href=\"https://doi.org/10.4103/ijp.IJP_651_16\">10.4103/ijp.IJP_651_16</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29326490/\">https://pubmed.ncbi.nlm.nih.gov/29326490</a></p></li><li><p>Alves, F, et al., &amp; Alvar, J (2018). Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. <i>Clinical microbiology reviews</i> 31(4) –. DOI:<a href=\"https://doi.org/10.1128/CMR.00048-18\">10.1128/CMR.00048-18</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30158301/\">https://pubmed.ncbi.nlm.nih.gov/30158301</a></p></li><li><p>Bissuel, F, et al., &amp; Trepo, C (1994). Absence of systemic absorption of oral paromomycin during long-term, high-dose treatment for cryptosporidiosis in AIDS. <i>The Journal of infectious diseases</i> 170(3) 749–750. DOI:<a href=\"https://doi.org/10.1093/infdis/170.3.749\">10.1093/infdis/170.3.749</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7915753/\">https://pubmed.ncbi.nlm.nih.gov/7915753</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07AA06;
